Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.80 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.80 |
| ▸ | EPHX1 | P07099 | 10/20 | 0.70 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.68 |
| ▸ | CASP2 | P42575 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.57 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.57 |
| ▸ | NAAA | Q02083 | 1/20 | 0.57 |
| ▸ | FAAH | O00519 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL75904 | 1.00 | KDM4E (0.80) | KDM4EMAPK1HIF1AEPHX1PAOX | |
| SCHEMBL2481694 | 1.00 | KDM4E (0.80) | KDM4EMAPK1HIF1AEPHX1PAOX | |
| SCHEMBL1481880 | 1.00 | KDM4E (0.80) | KDM4EMAPK1HIF1AEPHX1PAOX | |
| SCHEMBL14002535 | 1.00 | KDM4E (0.80) | KDM4EMAPK1HIF1AEPHX1PAOX | |
| SCHEMBL8204709 | 1.00 | KDM4E (0.80) | KDM4EMAPK1HIF1AEPHX1PAOX | |
| SCHEMBL25243376 | 1.00 | KDM4E (0.80) | KDM4EMAPK1HIF1AEPHX1PAOX | |
| SCHEMBL7990903 | 1.00 | KDM4E (0.80) | KDM4EMAPK1HIF1AEPHX1PAOX | |
| SCHEMBL559951 | 1.00 | KDM4E (0.80) | KDM4EMAPK1HIF1AEPHX1PAOX | |
| SCHEMBL8979293 | 1.00 | KDM4E (0.80) | KDM4EMAPK1HIF1AEPHX1PAOX | |
| SCHEMBL1457274 | 1.00 | KDM4E (0.80) | KDM4EMAPK1HIF1AEPHX1PAOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108866352-A | Process for producing lithium carbonate by extracting lithium in salt lake brine through phosphate ionic liquid | 青海柴达木兴华锂盐有限公司 | 2018-11-23 | — | — | CN | claimed |
| CN-104946889-B | A kind of method of extract and separate iron and aluminium from hydrochloric acid medium | 广州绿华环保科技有限公司 | 2017-10-27 | — | — | CN | claimed |
| CN-104946889-A | Method for extracting and separating iron and aluminum from hydrochloric acid media | GUANGZHOU LYUHUA ENVIRONMENTAL PROT SCIENCE & TECHNOLOGY CO LTD | 2015-09-30 | — | — | CN | claimed |
| WO-2008029278-A2 | CONJUGATES OF ANTITHROMBIN BINDING OLIGOSACCHARIDE DERIVATIVES AND THERAPEUTIC PROTEINS | ENDOTIS PHARMA S.A. (FR) | 2008-03-13 | — | — | WO | claimed |
| EP-1886696-A1 | Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins | Endotis Pharma (FR) | 2008-02-13 | — | — | EP | claimed |
| CN-1169791-C | Novel acetamide derivatives and protease inhibitors | �ձ���ҩ��ʽ���� | 2004-10-06 | — | — | CN | claimed |
| CN-1229405-A | Novel acetamide derivatives and protease inhibitors | NIPPON KAYAKU KK (JP) | 1999-09-22 | — | — | CN | claimed |
| CN-1033520-C | Solvent extraction method concentration process of gibberellin fermented filtrate | UNIV QINGHUA (CN) | 1996-12-11 | — | — | CN | claimed |
| US-20240239934-A1 | FUMARIC ACID DIESTER RESIN, FILM AND POLARIZING PLATE | TOSOH CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239934-A1 | FUMARIC ACID DIESTER RESIN, FILM AND POLARIZING PLATE | TOSOH CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2023242661-A2 | POLYMERIC TANDEM DYES WITH SPACING LINKER GROUPS | Sony Group Corporation (JP) | 2023-12-21 | — | — | WO | disclosed |
| US-11826430-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230241224-A1 | 2'-ALKYL OR 3'- ALKYL MODIFIED RIBOSE DERIVATIVES AND METHODS OF USE | SANEGENE BIO USA INC. | 2023-08-03 | — | — | US | disclosed |
| CN-1043319-A | New amine and uses thereof | MITSUI PHARMACEUTICALS (JP) | 1990-06-27 | — | — | CN | disclosed |
| US-4575734-A | LEVCO DYES | RICOH COMPANY, LTD. (JP) | 1986-03-11 | — | — | US | disclosed |
| US-4562448-A | Heat-sensitive transfer medium | RICOH CO., LTD. (JP) | 1985-12-31 | — | — | US | disclosed |
| US-4547788-A | SHEET HAVING LAYER CONTAINING LEVCO DYE; ACCEPTOR SHEET CONTAININGCOLORING AGENT; POROUS FILLER | RICOH COMPANY, LTD. (JP) | 1985-10-15 | — | — | US | disclosed |
| US-4089865-A | Certain thiazole compounds | SYNTEX (U.S.A.) INC. (US) | 1978-05-16 | — | — | US | disclosed |
| US-4001421-A | THIAZOLE CARDIOVASCULAR AGENTS | SYNTEX (U.S.A.) INC. (US) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | KDM4E 2656/4885MAPK1 148/4885HIF1A 4148/4885 |
| US-20230241224-A1 | 2'-ALKYL OR 3'- ALKYL MODIFIED RIBOSE DERIVATIVES AND METHODS OF USE | PARP1, PARP2, CD38 | KDM4E 3319/4885MAPK1 3770/4885HIF1A 1722/4885 |
| US-11826430-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | KDM4E 1808/4885MAPK1 3381/4885HIF1A 1581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.